Mesalazine-associated severe aplastic anemia successfully treated with antithymocyte globulin, cyclosporine and granulocyte colony-stimulating factor.
A 20-year-old male with ulcerative colitis complicated by mesalazine-associated severe aplastic anemia is described. The patient developed aplastic anemia four months after the start of mesalazine therapy. He was treated with antithymocyte globulin, cyclosporine, and granulocyte colony-stimulating factor (G-CSF) and responded well. Hematological complications of mesalazine are rare, but if bone marrow suppression is detected, immediate cessation of the drug and intensive immunosuppressive treatment with G-CSF should be considered.
Otsubo
H
H
Department of Internal Medicine (II), Jikei University School of Medicine, Tokyo, Japan.
Kaito
K
K
Sekita
T
T
Shimada
T
T
Kobayashi
M
M
Hosoya
T
T
D000328:Adult; D000741:Anemia, Aplastic / Q000139:chemically induced* / Q000188:drug therapy*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D016572:Cyclosporine / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D019804:Mesalamine / Q000009:adverse effects*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000961:Antilymphocyte Serum; D016179:Granulocyte Colony-Stimulating Factor; D019804:Mesalamine; D016572:Cyclosporine